Cedars-Sinai Discovery May Aid Doctors in Diagnosing At-risk Patients Before Symptoms Appear
A team led by a Cedars-Sinai physician-scientist has discovered a biomarker—a protein found in the blood—for the most common type of heart failure, a new study published today in JAMA Cardiology shows.
Heart failure with preserved ejection fraction (HFpEF) affects more than 6.5 million Americans each year. And now, thanks to the discovery of the first-ever biomarker for HFpEF, a simple blood test can reveal whether a patient’s heart is not making enough of an important protein. If the protein levels are decreased, the biomarker signal increases and physicians will be able to diagnose heart failure sooner, prescribe corrective medicines and prevent further disease progression.
“By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed,” said Robin Shaw, MD, PhD, the Wasserman Endowed Chair in Cardiology and professor of Medicine at the Smidt Heart Institute at Cedars-Sinai and principal investigator on the study. “Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed.”
Heart failure with preserved ejection fraction is a condition where the heart can contract, but has problems relaxing—limiting the heart’s ability to fill with blood between each beat—and therefore lowers the amount of blood moving forward with each contraction. Prior to the discovery of the biomarker, clinicians had to wait for patients to have symptoms to make a diagnosis of HFpEF and had to use an echocardiogram that measured how well the heart relaxed. There was no method to gauge the health of the heart muscle before symptoms developed or determine the severity of disease once symptoms were present.
The biomarker—named cBIN1 Score, or CS for short—allows doctors to measure muscle deterioration and measure a protein that regulates the heart’s ability to both contract and relax. As the protein decreases, CS increases, serving as an indication of onset heart failure. The CS biomarker can be measured using a simple blood draw.
This discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician. This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.
Eduardo Marbán, MD, PhD, director, Smidt Heart Institute
The CS biomarker is designed to be used in an outpatient clinic setting. For patients with known HFpEF, doctors can draw a CS level and use it to both guide current care, including medication adjustments, and predict the chances of a patient being admitted to the hospital in the next 12 months.
“More broadly, this discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician,” said Eduardo Marbán, MD, PhD, director of the Smidt Heart Institute. “This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.”
Symptoms of heart failure typically appear as fatigue, fluid weight gain, leg swelling and shortness of breath. Heart failure with preserved ejection fraction is typically diagnosed in elderly people or those living with high blood pressure, diabetes, elevated cholesterol, hypertension, obesity, obstructive sleep apnea, anemia, iron deficiency or diabetes. Its prevalence is projected to rise drastically over the coming decades. Previous studies have shown that women represent the majority of patients diagnosed with the disease.
As next steps, Cedars-Sinai researchers plan on identifying specialty populations in which the CS biomarker could be useful, including sex-based differences, those who have undergone a heart transplant or valve replacement, as well as individuals with no known heart disease or risk factors.
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Study finds inequities in access to heart failure careon October 29, 2019 at 2:03 am
Nationally, heart failure patients who receive specialized cardiology care after admission tend to have better outcomes, including lower readmission rates and lower rates of death. But not all ...
- Intermountain Healthcare sending 'golden tickets' to participants for heart disease studyon October 28, 2019 at 5:17 pm
Researchers announced Monday at the Intermountain Gardner Transformation Center that they are expanding a study that could better identify patients with heart disease. Teran had been chosen for the ...
- MyoKardia's MYK-491 shows positive effect in certain heart failure patientson October 28, 2019 at 11:03 am
MyoKardia (MYOK-0.5%) announces positive preliminary data from a Phase 2a clinical trial evaluating MYK-491 in patients with stable heart failure due to the inability of the left ventricle to pump ...
- Mom Takes On NYC Marathon for Son With Heart Disease Who Won’t Be Able to Run Oneon October 28, 2019 at 9:42 am
Two weeks later, Zachary was brought in for a heart check-up on Christmas Eve. To the surprise of his parents, the doctors diagnosed him with heart valve disease—a congenital heart defect that can ...
- Atrius Health, Verily team to better treat heart failure patientson October 27, 2019 at 9:51 pm
Atrius Health, New England’s largest independent medical group, has partnered with Alphabet’s life sciences division Verily to better treat heart failure patients and reduce their risk of ...
- Five warning signs of heart failure: Know them before it’s too lateon October 27, 2019 at 4:39 pm
Now they call 9-1-1. At the hospital, they’re given a frightening diagnosis: heart failure. This inevitably elicits questions — is my heart failing like a machine would? What heart failure actually ...
- Perceptions of Mobile Technology for Heart Failure Education and Self-Management Among Middle-Aged and Older Adultson October 25, 2019 at 12:00 pm
Mobile technology is a promising educational platform for chronic disease management. Patients with heart failure (HF) have high rates of hospitalization and complications. The goal of the current ...
- Orange peel nutrients studied as preventatives for cancer, obesity, heart diseaseon October 24, 2019 at 12:05 am
ORLANDO, Fla., Oct. 24 (UPI) --Nutrients found in orange rind and orange pith are getting a closer look from researchers in Texas and Florida as mouse studies show benefits for heart disease and ...
- Shockwaves Treat Heart Diseaseon October 23, 2019 at 8:13 pm
What happens when heart disease is so bad that thick plaque makes it nearly impossible to even place a stent in the arteries? Meet one woman who is part of a clinical trial using shockwaves to ...
via Bing News